Loading...
GUBRA logo

Gubra A/SCPSE:GUBRA Rapporto sulle azioni

Cap. di mercato DKK 5.2b
Prezzo delle azioni
DKK 321.00
DKK 469.5
31.6% sottovalutato sconto intrinseco
1Y-22.0%
7D0.5%
Valore del portafoglio
​
Vista

Gubra A/S

Report azionario CPSE:GUBRA

Capitalizzazione di mercato: DKK 5.2b

Gubra (GUBRA) Panoramica del titolo

Gubra A/S, una società biotecnologica, si concentra sulla ricerca pre-clinica a contratto e sulla scoperta di farmaci a base di peptidi nell'ambito delle malattie metaboliche e fibrotiche in Europa, Nord America e a livello internazionale. Maggiori dettagli

GUBRA analisi fondamentale
Punteggio fiocco di neve
Valutazione3/6
Crescita futura1/6
Prestazioni passate4/6
Salute finanziaria6/6
Dividendi0/6

Premi

Il rapporto prezzo/utile ( 3.1 x) è inferiore al mercato Danish ( 16.2 x)

È diventato redditizio quest'anno

Negoziato a un buon valore rispetto ai pari e al settore

Analisi del rischio

Si prevede che gli utili diminuiranno in media di 41.3% all'anno per i prossimi 3 anni

Prezzo delle azioni volatile negli ultimi 3 mesi rispetto al mercato Danish


GUBRA Community Fair Values

Create Narrative

See what 9 others think this stock is worth. Follow their fair value or set your own to get alerts.

Analyst Price Targets

View all narratives
UNCY logo
UNCYFeatured

Looking to be second time lucky with a game-changing new product

Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.
View narrative
Community Contributor
US$21.53FV • 64.4% sottovalutato sconto intrinseco
5419.8%Revenue growth p.a.
6.2k
18
0
129
3mo ago

Concorrenti di Gubra A/S

Storia dei prezzi e prestazioni

Riepilogo dei massimi, dei minimi e delle variazioni dei prezzi delle azioni per Gubra
Prezzi storici delle azioni
Prezzo attuale dell'azioneDKK 321.00
Massimo di 52 settimaneDKK 571.00
Minimo di 52 settimaneDKK 293.00
Beta0.45
Variazione di 1 mese-11.86%
Variazione a 3 mesi-30.79%
Variazione di 1 anno-22.01%
Variazione a 3 anni200.00%
Variazione a 5 annin/a
Variazione dall'IPO191.82%

Notizie e aggiornamenti recenti

GUBRA: Obesity Trial Pipeline Will Drive Long Term Upside

Analysts have kept their DKK 469.50 price target on Gubra unchanged, citing only minor tweaks to inputs such as discount rate, revenue growth, profit margin and forward P/E assumptions, rather than any shift in their overall view. What's in the News Gubra has called its annual general meeting for March 26, 2026, with the board proposing to renew and extend its authorization to issue warrants, including an increase of 120,277 warrants and an extension of the authorization period to March 26, 2031 (Key Developments).

GUBRA: Obesity Study And Ventures Unit Will Drive Long Term Upside

Analysts have kept their DKK 469.5 price target on Gubra unchanged, citing only marginal adjustments to assumptions such as the discount rate and forward P/E as the basis for this maintained view. What's in the News Gubra submitted a clinical trial application in Germany for GUB-UCN2, a first in human Phase 1/2a study designed to assess safety, tolerability, pharmacokinetics and preliminary efficacy, including muscle volume and muscle function endpoints, in about 188 participants across multiple indications and patient groups (Key Developments).

GUBRA: Obesity Trial And Ventures Expansion Will Drive Future Upside Potential

Analysts have kept their DKK price target for Gubra unchanged at DKK469.50, citing essentially stable assumptions on discount rate, revenue trajectory, profit margin and forward P/E as reasons to maintain their prior valuation view. What's in the News Clinical trial application submitted in Germany for GUB-UCN2, a first in human Phase 1/2a study targeting high quality weight loss, with about 188 participants across multiple indications and patient groups, including combination use with incretin based therapy for obesity (Product Related Announcement).

GUBRA: Future Obesity Trial And Ventures Platform Will Drive Upside Potential

Analysts have kept their DKK 469.5 price target on Gubra unchanged, citing model adjustments that reflect a slightly higher discount rate, softer revenue expectations, a lower projected profit margin and a higher future P/E multiple. What's in the News Gubra submitted a clinical trial application in Germany for GUB-UCN2, a first in human Phase 1/2a study aimed at high quality weight loss, with a design that looks at safety, tolerability, pharmacokinetics, preliminary efficacy, muscle volume and muscle function in about 188 participants, including both healthy volunteers and people living with obesity, as a standalone therapy and in combination with incretin based treatment.

Recent updates

GUBRA: Obesity Trial Pipeline Will Drive Long Term Upside

Analysts have kept their DKK 469.50 price target on Gubra unchanged, citing only minor tweaks to inputs such as discount rate, revenue growth, profit margin and forward P/E assumptions, rather than any shift in their overall view. What's in the News Gubra has called its annual general meeting for March 26, 2026, with the board proposing to renew and extend its authorization to issue warrants, including an increase of 120,277 warrants and an extension of the authorization period to March 26, 2031 (Key Developments).

GUBRA: Obesity Study And Ventures Unit Will Drive Long Term Upside

Analysts have kept their DKK 469.5 price target on Gubra unchanged, citing only marginal adjustments to assumptions such as the discount rate and forward P/E as the basis for this maintained view. What's in the News Gubra submitted a clinical trial application in Germany for GUB-UCN2, a first in human Phase 1/2a study designed to assess safety, tolerability, pharmacokinetics and preliminary efficacy, including muscle volume and muscle function endpoints, in about 188 participants across multiple indications and patient groups (Key Developments).

GUBRA: Obesity Trial And Ventures Expansion Will Drive Future Upside Potential

Analysts have kept their DKK price target for Gubra unchanged at DKK469.50, citing essentially stable assumptions on discount rate, revenue trajectory, profit margin and forward P/E as reasons to maintain their prior valuation view. What's in the News Clinical trial application submitted in Germany for GUB-UCN2, a first in human Phase 1/2a study targeting high quality weight loss, with about 188 participants across multiple indications and patient groups, including combination use with incretin based therapy for obesity (Product Related Announcement).

GUBRA: Future Obesity Trial And Ventures Platform Will Drive Upside Potential

Analysts have kept their DKK 469.5 price target on Gubra unchanged, citing model adjustments that reflect a slightly higher discount rate, softer revenue expectations, a lower projected profit margin and a higher future P/E multiple. What's in the News Gubra submitted a clinical trial application in Germany for GUB-UCN2, a first in human Phase 1/2a study aimed at high quality weight loss, with a design that looks at safety, tolerability, pharmacokinetics, preliminary efficacy, muscle volume and muscle function in about 188 participants, including both healthy volunteers and people living with obesity, as a standalone therapy and in combination with incretin based treatment.

GUBRA: Future Pipeline Milestones And Royalties Will Drive Upside Potential

Analysts have reduced their price target for Gubra from DKK 502.50 to DKK 469.50, reflecting updated views on discount rates, revenue contraction, profit margins and a significantly lower future P/E multiple. What's in the News Gubra plans an Analyst and Investor Day event, giving the market a closer look at its business model, pipeline and long term priorities (Key Developments).

AbbVie Agreement And Clinical Trials Will Unlock New Avenues

The significant downward revision in Gubra’s consensus price target reflects lowered expectations for future growth and earnings, as evidenced by reduced forecasts for both revenue growth and the future P/E multiple, resulting in a new fair value estimate of DKK540. What's in the News Extraordinary cash dividend of DKK 1 billion (DKK 61.2 per share) approved at EGM.

Gubra A/S' (CPH:GUBRA) 35% Jump Shows Its Popularity With Investors

Jun 28
Gubra A/S' (CPH:GUBRA) 35% Jump Shows Its Popularity With Investors
User avatar

AbbVie Agreement And Clinical Trials Will Unlock New Avenues

Strategic partnerships and collaborations with top pharma companies ensure sustainable revenue streams and growth opportunities for Gubra.

We're Not Worried About Gubra's (CPH:GUBRA) Cash Burn

May 04
We're Not Worried About Gubra's (CPH:GUBRA) Cash Burn

Gubra A/S' (CPH:GUBRA) 26% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio

Mar 11
Gubra A/S' (CPH:GUBRA) 26% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio

We're Not Very Worried About Gubra's (CPH:GUBRA) Cash Burn Rate

Jan 14
We're Not Very Worried About Gubra's (CPH:GUBRA) Cash Burn Rate

Gubra A/S' (CPH:GUBRA) Shares Climb 25% But Its Business Is Yet to Catch Up

Jun 19
Gubra A/S' (CPH:GUBRA) Shares Climb 25% But Its Business Is Yet to Catch Up

Subdued Growth No Barrier To Gubra A/S (CPH:GUBRA) With Shares Advancing 60%

Mar 07
Subdued Growth No Barrier To Gubra A/S (CPH:GUBRA) With Shares Advancing 60%

Rendimenti per gli azionisti

GUBRADK Life SciencesDK Mercato
7D0.5%-1.0%2.4%
1Y-22.0%-16.5%-15.9%

Ritorno vs Industria: GUBRA ha avuto una performance inferiore rispetto al Danish Life Sciences che ha registrato un rendimento -16.5 % nell'ultimo anno.

Rendimento vs Mercato: GUBRA ha avuto una performance inferiore al mercato Danish che ha registrato un rendimento -15.9 % nell'ultimo anno.

Volatilità dei prezzi

Is GUBRA's price volatile compared to industry and market?
GUBRA volatility
GUBRA Average Weekly Movement8.4%
Life Sciences Industry Average Movement7.3%
Market Average Movement4.9%
10% most volatile stocks in DK Market9.4%
10% least volatile stocks in DK Market2.9%

Prezzo delle azioni stabile: Negli ultimi 3 mesi il prezzo delle azioni di GUBRA è stato volatile rispetto al mercato Danish.

Volatilità nel tempo: La volatilità settimanale ( 8% ) di GUBRA è rimasta stabile nell'ultimo anno, ma è comunque superiore al 75% delle azioni Danish.

Informazioni sull'azienda

FondatoI dipendentiAMMINISTRATORE DELEGATOSito web
2008300Markus Rohrwildwww.gubra.dk

Gubra A/S, azienda biotecnologica, si concentra sulla ricerca pre-clinica a contratto e sulla scoperta di farmaci a base di peptidi nell'ambito delle malattie metaboliche e fibrotiche in Europa, Nord America e a livello internazionale. L'azienda opera attraverso tre segmenti: Ricerca pre-clinica a contratto (CRO), Scoperta e partnership e Gubra Green. Offre servizi di ricerca e sviluppo preclinico a contratto nell'ambito delle malattie metaboliche e fibrotiche per l'industria farmaceutica e biotecnologica, oltre a fornire servizi di farmacologia in vivo, saggi di biomarcatori, bioinformatica, sequenziamento next gen, farmacocinetica e istologia 2D e 3D con intelligenza artificiale.

Gubra A/S Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di Gubra con la sua capitalizzazione di mercato?
GUBRA statistiche fondamentali
Capitalizzazione di mercatoDKK 5.24b
Utili (TTM)DKK 1.69b
Ricavi(TTM)DKK 2.64b
3.1x
Rapporto P/E
2.0x
Rapporto P/S

GUBRA è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Utili e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
GUBRA Conto economico (TTM)
RicaviDKK 2.64b
Costo del fatturatoDKK 80.08m
Profitto lordoDKK 2.56b
Altre speseDKK 866.16m
UtiliDKK 1.69b

Ultimi utili riportati

Dec 31, 2025

Prossima data di guadagno

Aug 20, 2026

Utile per azione (EPS)103.51
Margine lordo96.96%
Margine di profitto netto64.11%
Rapporto debito/patrimonio netto0%

Come si è comportato GUBRA nel lungo periodo?

Vedi performance storica e confronto

Analisi aziendale e situazione dei dati finanziari

DatiUltimo aggiornamento (ora UTC)
Analisi dell'azienda2026/05/03 02:16
Prezzo dell'azione a fine giornata2026/05/01 00:00
Utili2025/12/31
Utili annuali2025/12/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

PacchettoDatiTempisticaEsempio Fonte USA *
Dati finanziari della società10 anni
  • Conto economico
  • Rendiconto finanziario
  • Bilancio
Stime di consenso degli analisti+3 anni
  • Previsioni finanziarie
  • Obiettivi di prezzo degli analisti
Prezzi di mercato30 anni
  • Prezzi delle azioni
  • Dividendi, scissioni e azioni
Proprietà10 anni
  • Top azionisti
  • Insider trading
Gestione10 anni
  • Team di leadership
  • Consiglio di amministrazione
Sviluppi principali10 anni
  • Annunci aziendali

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

Gubra A/S è coperta da 3 analisti. 2 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

AnalistaIstituzione
Rune DahlDNB Carnegie
Jesper IlsøeDNB Carnegie
Rajan SharmaGoldman Sachs